<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| ME-16, ME-H                | External request: Submission from Bayer Healthcare Pharmaceuticals (12/10/18) to review and consider data for potential tumor agnostic inclusion of larotrectinib as follows:  
  - ME-16: For treatment of metastatic disease modify footnote "oo" to add “Obtain tissue to test for NTRK gene fusion. Larotrectinib is recommended for NTRK-positive tumors.”  
  - ME-I: Add “Larotrectinib if NTRK gene fusion positive” as a systemic therapy option for metastatic or unresectable disease  
  - MS-8: For workup, add “NTRK testing should be conducted as part of broad molecular testing.”                                                                                   | YES 1 NO 1 ABSTAIN 2 ABSENT 8 |
|                            | Based on a review of data from the submission, the panel vote supported adding “Larotrectinib for NTRK gene fusion positive tumors” as a second-line or subsequent systemic therapy option for metastatic or unresectable disease. Larotrectinib has been preference stratified as “Useful In Certain Circumstances.”  
  Further information regarding the NTRK gene fusions in melanoma was added to the new Principles of Molecular Testing document (ME-C).  
  References:  